EBMT Activity Survey Teams Patients Transplants

Slides:

Advertisements

Similar presentations

Hematopoietic Stem Cell Transplantation Lynn Savoie September 30, 2006.

Advertisements

Hematopoietic stem cell transplantation

Bone Marrow Transplant in Oncology. Source Pathology  Treat Leukemia by chemotherapy  Regeneration of normal marrow  Chemotherapy alone cannot eliminate.

Hematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate Clinical Professor,

Transplantation of hematopoietic stem cells in pediatric oncology Vladivostok State Medical University Foreign languages department Vladivostok 2012 Scientific.

CLINICAL CODING FOR BM & PBSC TRANSPLANT PROCEDURES Dr Kim Orchard – Transplant Director Carol Hurlock – Data Manager Wessex Blood and Marrow Transplantation.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.

Allogeneic Stem Cell Transplantation: The Journey

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.

CHAPTER 1 BLOOD AND MARROW TRANSPLANTATION Editors: Dr Alan Teh Kee Hean Prof Dr Chan Lee Lee Expert Panel: Dr Alan Teh Kee Hean (co-chairperson) Prof.

Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation, Year New transplant patients Deaths

(A) the hematopoietic stem cell transplanted (HSCT) recipients only (B) both autologous and allogeneic transplanted recipients (C) both solid organ and.

Bone Marrow Donation. What is Bone marrow?  flexible spongy tissue in the interior of bones such as your hip and thigh.  constitutes 4% of the total.

Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation, Year New transplant patients Deaths

Hematopoietic Stem Cell Transplantation (HSCT)

Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors N Engl J Med 2012;367: R3 Sunhee park/Prof. Kyung-sam cho.

Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

The Complex Relationship between Human Herpesvirus 6 and Acute Graft-versus-Host Disease Claire Pichereau, Kristell Desseaux, Anne Janin, Catherine Scieux,

EBMT Activity Survey Teams Patients Transplants

EBMT Registry Update Shelley Hewerdine

HS 4160 Critical Scientific Analysis

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

EBMT Activity Survey Teams 39,313 Patients 43,636 Transplants

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors Mitchell S. Cairo,

Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:

Clinical Utility of Wilms' Tumor 1 Monitoring in Patients with Myeloid Malignancy and Prior Allogeneic Hematopoietic Stem Cell Transplantation Kazuko.

Timing for HCT Consultation

Cord blood transplantation and stem cell regenerative potential

Letermovir(Prevymis™) Guidelines for Inpatient Use

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation Mats Remberger, Emma.

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation,

LONG TERM Outcomes of Pediatric Patients with Malignant and NON-Malignant Disorders Receiving Α/Β T-CELL Depleted HLA-Haploidentical Hematopoietic STEM.

The Complex Relationship between Human Herpesvirus 6 and Acute Graft-versus-Host Disease Claire Pichereau, Kristell Desseaux, Anne Janin, Catherine Scieux,

Bacteremia in Blood or Marrow Transplantation Patients: Clinical Risk Factors for Infection and Emerging Antibiotic Resistance Allison M. Bock, Qing.

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Biology of Blood and Marrow Transplantation

Donor Selection in T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies Stefan O. Ciurea, Richard.

Kasiani C. Myers, Stella M. Davies

Cutaneous Complications in Hematopoietic Cell Transplant Recipients: Impact of Biopsy on Patient Management Oana Paun, Tycel Phillips, Pingfu Fu, Roberto.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.

Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia John Moore, Ian Nivison-Smith,

Aplastic Anemia: Pathophysiology and Treatment

Hematopoietic Stem Cell Transplantation Dr . Ghassemi A Associate professor of pediatric Hematologist Oncologist & stem cell transplantation.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Clinical Lymphoma, Myeloma and Leukemia

Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation J.R. Molina,

Bridge to transplant following Bv+Bs regimen.

Eliane Gluckman Experimental Hematology

Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors Petter Svenberg, Mats Remberger, Johan Svennilson, Jonas.

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based.

Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies Mary Eapen, Paul O'Donnell,

Effect of donor and recipient CMV serostatus on survival after HSCT in 2 large cohorts. Effect of donor and recipient CMV serostatus on survival after.

Mary Eapen Biology of Blood and Marrow Transplantation

Presentation transcript:

EBMT Activity Survey 2014 656 Teams 36 469 Patients 40 829 Transplants 47 Countries For internal use only. For any other use, please contact Helen Baldomero for permission: helen.baldomero@usb.ch

EBMT Activity Survey in 2014: Patient and transplant numbers Allogeneic HSCT Autologous Total 1st allo/1st auto HSCT Retransplants Additional transplants TOTAL Teams: 656 (of 680) Countries reporting data: 47 15765 1105 76 16946 20704 1594 1585 23883 36469 2699 1661 40829 Indication Baldomero: Transplant Activity Survey Dec 2015

EBMT Activity Survey in 2014: Donor type and stem cell source: all transplants PBSC Allogeneic total HLA-id HLA-non id Syngeneic Unrelated Autologous 3766 1528 717 6 1515 102 16946 6003 1961 23 8959 23883 Total 12548 4436 1240 17 6855 23778 Donor type Stem Cell Source Cord 632 39 4 589 3 Baldomero: Transplant Activity Survey Dec 2015

EBMT Activity Survey 2014: Main indications Allogeneic 1st HSCT Baldomero: Transplant Activity Survey Dec 2015 EBMT Activity Survey 2014: Main indications Allogeneic 1st HSCT Autologous Total Leukemia Lymphoma Plasma Cell disorder Solid tumor Non-malignant disorders Bone marrow failure Other Total 1st Transplants 11348 1712 580 44 1942 833 139 15765 505 8089 10421 1414 261 4 14 20704 11853 9801 11001 1458 2203 837 153 36469 Indication

Allogeneic HSCT in Europe 2014 1st HSCT Baldomero: Transplant Activity Survey Dec 2015

Autologous HSCT in Europe 2014 1st HSCT Baldomero: Transplant Activity Survey Dec 2015

HSCT Activity in Europe 1990-2014: Baldomero: Transplant Activity Survey Dec 2015 HSCT Activity in Europe 1990-2014: Transplant type 1st HSCT

HSCT Activity in Europe 1990-2014: Baldomero: Transplant Activity Survey Dec 2015 HSCT Activity in Europe 1990-2014: Donor origin: 1st HSCT

HSCT Activity in Europe 1990-2014: Baldomero: Transplant Activity Survey Dec 2015 HSCT Activity in Europe 1990-2014: Main Indications: allogeneic

HSCT Activity in Europe 1990-2014: Main Indications: autologous Baldomero: Transplant Activity Survey Dec 2015